Latest filings (excl ownership)
6-K
Affimed Reports 2023 Financial Results and Operational Progress
28 Mar 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Current report (foreign)
11 Mar 24
6-K
Affimed Announces 1-for-10 Reverse Stock Split
6 Mar 24
6-K
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype
8 Jan 24
6-K
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
8 Jan 24
6-K
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1
11 Dec 23
6-K
Current report (foreign)
30 Nov 23
6-K
Unaudited consolidated interim statements of comprehensive loss
14 Nov 23
6-K
Affimed Announces Listing Transfer to NASDAQ Capital Markets
4 Oct 23
6-K
Unaudited consolidated interim statements of comprehensive loss
10 Aug 23
6-K
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
22 Jun 23
6-K
Data update from AFM24-101 phase 1/2 monotherapy study includes 15 patients from the EGFR mutant non-small cell lung cancer (NSCLC) cohort
5 Jun 23
6-K
Unaudited consolidated statements of comprehensive loss
23 May 23
6-K
Affimed Announces Annual General Meeting of Shareholders
22 May 23
6-K
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding
6 Apr 23
S-8
Registration of securities for employees
23 Mar 23
424B5
Prospectus supplement for primary offering
23 Mar 23
6-K
Affimed Reports 2022 Financial Results and Operational Progress
23 Mar 23
20-F
2022 FY
Annual report (foreign)
23 Mar 23
6-K
Affimed Reports on Corporate Progress and Provides
9 Jan 23
6-K
Affimed Provides Updated Clinical Data from Phase 1/2 Study of
12 Dec 22
6-K
Current report (foreign)
15 Nov 22
6-K
Affimed and Artiva Biotherapeutics Announce Partnership to Advance
3 Nov 22
6-K
Current report (foreign)
11 Aug 22
6-K
Current report (foreign)
23 Jun 22
6-K
Current report (foreign)
1 Jun 22
6-K
Affimed Announces Annual General Meeting of Shareholders
24 May 22
6-K
Current report (foreign)
18 Apr 22
424B5
Prospectus supplement for primary offering
14 Apr 22
424B5
Prospectus supplement for primary offering
12 Apr 22
6-K
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human
11 Apr 22
EFFECT
Notice of effectiveness
7 Apr 22
POS AM
Prospectus update (post-effective amendment)
31 Mar 22
20-F
2021 FY
Annual report (foreign)
31 Mar 22
6-K
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
31 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
31 Mar 22
6-K
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022
6 Jan 22
6-K
Current report (foreign)
9 Dec 21
6-K
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate
22 Nov 21
Latest ownership filings
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 24
SC 13G/A
683 Capital Management, LLC
13 Feb 24
SC 13G/A
BlackRock Inc.
7 Jul 23
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G/A
683 Capital Management, LLC
14 Feb 23
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
SC 13G
BlackRock Inc.
9 May 22
SC 13G
Gilde Healthcare Holding B.V.
21 Apr 22
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 22
SC 13G/A
BlackRock Inc.
7 Feb 22
SC 13G
683 Capital Management, LLC
7 Feb 22
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
21 Apr 21
SC 13G
Ridgeback Capital Investments L.P.
14 Apr 21
SC 13G/A
Stonepine Capital Management, LLC
12 Feb 21
SC 13G/A
MORGAN STANLEY
10 Feb 21
SC 13G
Point72 Asset Management, L.P.
8 Feb 21
SC 13G/A
BlackRock Inc.
29 Jan 21
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
19 Jan 21
SC 13G
MORGAN STANLEY
18 Dec 20
SC 13G
Assenagon Asset Management S.A.
17 Jun 20
SC 13G
Assenagon Asset Management S.A.
16 Jun 20
SC 13G
Assenagon Asset Management S.A.
16 Jun 20
SC 13G
INTEGRATED CORE STRATEGIES (US) LLC
26 May 20
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 May 20
SC 13G/A
Beneficial ownership report (amended)
13 Feb 20
SC 13G
Beneficial ownership report
7 Feb 20
SC 13G/A
Affimed N.V.
29 Jan 20
SC 13G/A
Affimed N.V.
8 Jan 20
SC 13G
Affimed N.V.
16 Dec 19
SC 13D/A
Affimed N.V.
18 Nov 19
SC 13D/A
Affimed N.V.
11 Apr 19
SC 13D/A
Affimed N.V.
9 Apr 19
SC 13D/A
Affimed N.V.
5 Apr 19
SC 13D/A
Affimed N.V.
2 Apr 19
SC 13G/A
Affimed N.V.
14 Feb 19
SC 13G/A
Affimed N.V.
12 Feb 19
SC 13G/A
Affimed N.V.
25 Jan 19